FY2025 EPS Forecast for Corcept Therapeutics Cut by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research cut their FY2025 earnings per share estimates for shares of Corcept Therapeutics in a research note issued to investors on Wednesday, December 18th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $1.55 per share for the year, down from their previous estimate of $1.56. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis.

Several other research analysts have also recently commented on the company. Truist Financial increased their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler upped their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $51.40 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The business has a 50-day moving average of $53.83 and a 200-day moving average of $42.03. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of 40.79 and a beta of 0.51. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $62.22.

Institutional Trading of Corcept Therapeutics

A number of institutional investors have recently bought and sold shares of CORT. Nisa Investment Advisors LLC boosted its stake in shares of Corcept Therapeutics by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 510 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Corcept Therapeutics by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 46,100 shares of the biotechnology company’s stock worth $1,498,000 after purchasing an additional 1,200 shares during the period. Calamos Advisors LLC acquired a new position in Corcept Therapeutics in the second quarter valued at about $373,000. Allspring Global Investments Holdings LLC lifted its position in Corcept Therapeutics by 0.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock worth $4,138,000 after purchasing an additional 541 shares during the period. Finally, Legato Capital Management LLC grew its stake in Corcept Therapeutics by 56.5% during the second quarter. Legato Capital Management LLC now owns 24,056 shares of the biotechnology company’s stock worth $782,000 after buying an additional 8,680 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Insider Activity

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the completion of the sale, the insider now owns 8,494 shares of the company’s stock, valued at $481,779.68. This trade represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,811 shares of company stock valued at $1,341,360 over the last ninety days. 20.50% of the stock is currently owned by company insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.